4.42  -0.09 (-2%)		06-17 10:41
Open: 4.46 High: 4.55 Volume: 30,801		Pre. Close: 4.51 Low: 4.2825 Market Cap: 19(M)

Short term
Mid term
Targets	6-month :	6.2	1-year :	7.24
Resists	First :	5.3	Second :	6.2
Pivot price	4.29
Supports	First :	4.05	Second :	3.27
MAs	MA(5) :	4.44	MA(20) :	4.11
	MA(100) :	4.13	MA(250) :	4.7
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	48.4	D(3) :	51.2
RSI	RSI(14): 56.5
52-week	High :	20.82	Low :	1.79

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ CING ] has closed below upper band by 33.5%. Bollinger Bands are 35.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4.58 - 4.61	4.61 - 4.64
Low:	4.14 - 4.17	4.17 - 4.2
Close:	4.46 - 4.51	4.51 - 4.55

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Wed, 11 Jun 2025
Cingulate Inc Approves Key Proposals at Annual Meeting - TipRanks

Tue, 20 May 2025
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - Stock Titan

Tue, 20 May 2025
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - GlobeNewswire

Wed, 14 May 2025
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 - GlobeNewswire

Wed, 14 May 2025
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 - Stock Titan

Tue, 13 May 2025
Cingulate Inc Terminates Grant Agreement with Foundation - TipRanks

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	4 (M)
Shares Float	4 (M)
Held by Insiders	2.4 (%)
Held by Institutions	3.2 (%)
Shares Short	144 (K)
Shares Short P.Month	172 (K)

EPS	-4.04
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.54
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-114.2 %
Return on Equity (ttm)	-358.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-2.32
Sales Per Share	0
EBITDA (p.s.)	-3.71
Qtrly Earnings Growth	0 %
Operating Cash Flow	-14 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-1.12
PEG Ratio	0
Price to Book value	2.89
Price to Sales	0
Price to Cash Flow	-1.34

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.